Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Epirubicin
Sponsor: SCRI Development Innovations, LLC
Collaborators: Aventis Pharmaceuticals|Pharmacia and Upjohn